Start / PharmaTalkRadio / How to make patient involvement sustainable throughout medicines development

PharmaTalkRadio

How to Make Patient Involvement Sustainable Throughout Medicines Development

30 min • 12 januari 2019

To prevent ticking off a box and to ensure that patient involvement is systemic and sustainable, we have to move into patient-centricity 2.0. What does this mean and how is this done so we can turn the patient voice into value, impact, and benefit? This session presented at the 2nd annual Patients as Partners EU meeting, which took place January 2018 in London, demonstrates best practices from Hoffman La Roche, Melanoma Patient Network, Patient Focused Medicines Development, and European Patients Forum. Moderated by: Bettina Ryll, PhD, Founder, Melanoma Patient Network Europe. Panelists: Nicola Bedlington, Secretary General, European Patients ForumNicholas Brooke, Chief Executive Officer, Patient Focused Medicines Development (PFMD)Irmi Gallmeier, Senior International Health Policy Leader, Patient Relations, F. Hoffman La Roche The 3rd annual Patients as Partners EU meeting will take place January 28-29, 2019 in London, UK. Find more information here.

Senaste avsnitt

Directors' Talk DPHARM 2025 - AI Sessions; Part III

25 juli | 6 min

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

25 juli | 20 min

Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches

25 juli | 29 min

Catalyzing Change: The Business Imperative of Patient-Centric Drug Development

21 juli | 26 min

How Emerging Biopharma CMOs Can Better Partner with Patient Organizations

21 juli | 32 min

Podcastbild

00:00 -00:00

Podcastbild

00:00 -00:00